CN104225034B - Application of composition in preparing medicine for treating non-infectious urethral syndrome - Google Patents
Application of composition in preparing medicine for treating non-infectious urethral syndrome Download PDFInfo
- Publication number
- CN104225034B CN104225034B CN201310243458.5A CN201310243458A CN104225034B CN 104225034 B CN104225034 B CN 104225034B CN 201310243458 A CN201310243458 A CN 201310243458A CN 104225034 B CN104225034 B CN 104225034B
- Authority
- CN
- China
- Prior art keywords
- parts
- filtering
- traditional chinese
- ethanol under
- extracting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses application of a composition in preparing a medicament for treating non-infectious urethral syndrome. The traditional Chinese medicine composition disclosed by the invention is prepared from 8 traditional Chinese medicines such as astragalus, talcum, selfheal and the like, and can be used for regulating qi, promoting diuresis, softening hardness and dissipating stagnation.
Description
Technical Field
The invention relates to a new application of a composition, in particular to an application of a traditional Chinese medicine composition in preparing a medicine for treating non-infectious urethral syndrome.
Background
The non-infectious urethral syndrome refers to the symptoms of only frequent micturition, urgent micturition and/or painful urination, while the middle section urine bacteria is negative in quantitative culture, and the urinary tract infection caused by bacteria (including tubercle bacillus), fungi, anaerobes, chlamydia and other microorganisms is eliminated.
The ancient Chinese medical science is comprehensively viewed, and although the disease name of the non-infectious urethral syndrome is not seen, the traditional Chinese medical science belongs to the scope of stranguria of the traditional Chinese medicine from the aspects of clinical manifestation and pathogenesis of the disease. The traditional Chinese medicine considers that the occurrence of the disease is closely related to the viscera such as kidney, liver, spleen and the like. The kidney can open and close, the bladder is a 'solitary house', and is a urine storage and excretion organ, and the kidney and the bladder are in exterior and interior and physiologically complete the function of gasifying and excreting body fluid; the book Su Wen & Ling lan Mi Dian Lun (Su Wen & Ling Mi Lun) is characterized by: so qi transformation can be expressed when the body fluids are stored in the bladder, so it is related to the kidneys. Zhu Dan xi Yun: "Qi and blood are mixed, and all diseases are not born, but only the stagnation is caused, so all diseases are born; the book of syndrome treatment Hui Bu (syndrome treatment Hui Qi) says: the disease is considered to be related to liver depression if it leads to full depression of heart and kidney, so that yin and yang are lambertian, and clear turbidity is coherent and is accumulated in lower jiao bladder, while water passage is astringent and so on. In Ling Shu & kou Wen chapter: "deficient middle-jiao and urine are the changes"; li Dongyuan also discusses that the spleen and stomach are the dominance of yin fire and that original qi blocks down-flow, i.e. clear qi does not grow and nine orifices are adverse in the theory of spleen and stomach and the theory of spleen deficiency and nine orifices; the "Zhu Danxi & urine obstruction" clearly indicates that the disease is related to the spleen because of the observation that qi is elevated, water is self-descending when qi is elevated, and water is carried by qi. Huangxiaoming [ experience introduction of Huangxiaoming for treating urethral syndrome [ J ] Zhejiang traditional Chinese and western medicine combination journal 200515, (2): 114- & ltSUB & gt 115 & gt indicates that the disease is located in the bladder and the affected viscera are mainly related to the heart, liver and kidney. The heart is the main spirit of the zang-fu organs; the heart meridian of hand shaoyin and the small intestine meridian of hand taiyang belong to each other, so the heart and the small intestine are exterior-interior, and the function of the small intestine in separating clear from turbid is related to the amount of urine; the liver meridian of foot jueyin starts from … … behind the toe nail of foot, enters into the yin hair along the medial line of thigh, winds around the yin organ, and reaches at least the abdomen … … "; the kidney and bladder are exterior-interior to each other and both dominate water, which enters the small intestine and descends to the uterus to move yin, resulting in scanty urine. Therefore, dysfunction of the above zang-fu organs will affect the normal micturition function of the bladder, causing frequent, urgent and painful urination.
The medicine of the invention is developed by combining the treatment principles of invigorating spleen and tonifying kidney, promoting diuresis and resolving masses by adopting the qi-regulating method and the clinical medication experience of many years, and is based on a large-dose qi-tonifying medicine, as discussed in Zhang Jingyue: "the fu bladder stores water, and the water enters the fu bladder and transforms water into qi, so there is qi and water; the water also flows out to reach qi, so there is water drowning; recorded as gasification, can output ! The cover is changed into the cover, then changed into the cover, and changed out, and changed into the cover, and. … … at present, for those who are closed due to qi deficiency, they have to use exhaustion of true yang, no root in Yuan-Hai, water-fire disharmony, and yin-yang disharmony, so qi turns from qi to qi but water turns from water to water, and water turns from water to water but water stores water, so the treatment must be "achieved. Aiming at the factors of blood stasis, vital essence failure, qi stagnation, phlegm coagulation, heat stagnation and the like of the disease targets, the traditional Chinese medicine adopts the effects of clearing damp, promoting heat and guiding water, softening hardness, dissipating stagnation, removing blood stasis, dredging qi-flowing machine, dispersing obstruction to treat the targets, recovering the normal qi transformation of the triple energizer, strengthening spleen, tonifying kidney, promoting diuresis and dissipating stagnation. The formula has ingenious conception and precise and appropriate compatibility, is treated by combining pathological analysis and pharmacological research of modern medicine in due time according to the theory of traditional Chinese medicine, has bright idea and is innovative.
The invention is an improved invention based on Chinese patent ZL 200410091455.5, and the content of the patent document is cited in the whole content. The chinese patent ZL 200410091455.5 does not describe the application of the Chinese medicinal composition in the preparation of the medicament for treating non-infectious urethral syndrome.
Disclosure of Invention
The invention aims to provide application of a composition in preparing a medicament for treating non-infectious urethral syndrome.
The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight:
30-150 parts of astragalus mongholicus, 7-28 parts of talcum, 10-40 parts of selfheal, 7-28 parts of glossy privet fruit
10-40 parts of lychee seed, 1-4 parts of amber, 1.5-6 parts of cinnamon, and 3-15 parts of phellodendron bark.
Preferably, the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight:
70 parts of astragalus mongholicus, 14 parts of talcum, 21 parts of selfheal and 14 parts of glossy privet fruit
Litchi seeds 21 parts, amber 2.1 parts, cinnamon 2.8 parts, phellodendron bark 7 parts.
Or:
30 parts of astragalus mongholicus, 7 parts of talcum, 10 parts of selfheal and 7 parts of glossy privet fruit
Litchi seeds 10 parts of amber 1 part of cinnamon 1.5 parts of phellodendron bark 3 parts.
Or:
astragalus root 150 parts talc 28 parts prunella spike 40 parts ligustrum japonicum 28 parts
40 parts of lychee seeds, 4 parts of amber, 6 parts of cinnamon and 15 parts of golden cypress. Or:
30 parts of astragalus mongholicus, 28 parts of talc, 10 parts of selfheal and 28 parts of glossy privet fruit
Litchi seeds 10 parts, amber 4 parts, cinnamon 1.5 parts, phellodendron bark 15 parts.
The traditional Chinese medicine of the invention can be replaced by traditional Chinese medicines with the same or similar effects, and the traditional Chinese medicines can be processed according to national traditional Chinese medicine processing standard or traditional Chinese medicine dictionary.
The active ingredients of the Chinese medicinal composition can be prepared by a conventional extraction process [ such as Vanbitsin traditional Chinese medicine pharmacy (1 st 12 months 1997, Shanghai scientific Press), and more preferably, the active ingredients of the Chinese medicinal composition are prepared by the following steps:
(1) weighing the traditional Chinese medicinal materials according to the weight part ratio of the raw material medicines, respectively cleaning and crushing;
(2) extracting radix astragali and cortex Phellodendri with 50-70% ethanol under reflux for 0.5-3 hr for 1-3 times, filtering the extractive solutions, mixing, recovering ethanol under reduced pressure, and concentrating to obtain fluid extract with relative density of 1.20-1.25;
(3) extracting fructus Ligustri Lucidi with 6-10 times of 70-90% ethanol under reflux for 1-3 times (1-3 hr for each time), filtering the extractive solutions, mixing, recovering ethanol under reduced pressure, and concentrating to obtain fluid extract with relative density of 1.20-1.25;
(4) soaking the cinnamon in 4-8 times of water for 1-2 hours, extracting volatile oil for 2-6 hours, collecting the volatile oil in another container, filtering and collecting the water extract, and reserving residues for later use;
(5) taking selfheal, lychee seeds and the residues obtained in the step (4), adding 8-10 times of water, decocting twice, wherein the first time is 1-3 hours, the second time is 1-2 hours, filtering the extracting solution, combining, adding the aqueous solution obtained in the step (4), and concentrating into clear paste with the relative density of 1.20-1.25 for later use;
(6) pulverizing pulvis Talci and Succinum into 100 mesh fine powder;
the clear paste obtained in the step (2), the clear paste obtained in the step (3), the volatile oil obtained in the step (4), the clear paste obtained in the step (5) and the fine powder obtained in the step (6) together form the active ingredient of the traditional Chinese medicine composition.
The preparation formulation of the traditional Chinese medicine composition provided by the invention is capsules, tablets, oral liquid or pills.
The invention also provides a preparation method of the Chinese medicinal composition capsule, which comprises the following steps:
(1) respectively cleaning and selecting the traditional Chinese medicinal materials, crushing, and weighing according to a proportion;
(2) extracting radix astragali and cortex Phellodendri with 50-70% ethanol under reflux for 0.5-3 hr for 1-3 times, preferably for 1-2 times, 8-12 times for the first time, 1-3 hr for the second time, 6-9 times for the second time, 0.5-2 hr for the second time, filtering the extractive solutions, mixing, recovering ethanol under reduced pressure, concentrating to obtain fluid extract with relative density of 1.20-1.25, and vacuum drying to obtain dry extract;
(3) extracting fructus Ligustri Lucidi with 6-10 times of 70-90% ethanol under reflux for 1-3 times (1-3 hr for each time), filtering the extractive solutions, mixing, recovering ethanol under reduced pressure, concentrating to obtain fluid extract with relative density of 1.20-1.25, and vacuum drying to obtain dry extract;
(4) soaking Cinnamomum cassia in 4-8 times of water for 1-2 hr, extracting volatile oil for 2-6 hr, collecting volatile oil with another container until the oil yield is not less than l.0%, filtering the water extractive solution, and collecting the residue;
(5) taking selfheal, lychee seeds and the residue obtained in the step (4), adding 8-10 times of water, decocting twice, wherein the first time is 1-3 hours, the second time is 1-2 hours, filtering the extracting solution, merging, adding the aqueous solution obtained in the step (4), concentrating into clear paste with the relative density of 1.20-1.25, drying in vacuum, mixing the obtained dry paste with the dry paste obtained in the step (2) and the dry paste obtained in the step (3), and crushing into 100-mesh powder for later use;
(6) pulverizing pulvis Talci and Succinum into 100 mesh powder;
(7) uniformly mixing the dry paste powder obtained in the step (5), the fine powder obtained in the step (6) and a proper amount of auxiliary materials, using 80% ethanol as a binding agent, stirring at a high speed for granulation, drying at 60-70 ℃, and finishing granules;
(8) and (4) screening out fine powder, spraying the volatile oil obtained in the step (4), uniformly mixing with the granules, sealing, and encapsulating to obtain the capsule.
The Chinese medicinal composition has Latin name of active ingredient as raw material medicine and its preparation method from Chinese medicinal dictionary (7 months 1977, first edition, Shanghai science and technology Press) and Chinese pharmacopoeia (2005 edition, chemical industry Press).
The traditional Chinese medicine composition can be prepared into any pharmaceutically acceptable conventional dosage forms, such as capsules, tablets, granules, powder, oral liquid or pills and the like, according to a conventional preparation process, for example, a preparation process recorded in Vanbitsin traditional Chinese medicine pharmacy (published by Shanghai science, 1997, 12 months, 1 st edition).
In the application of the invention, the preparation formulation of the traditional Chinese medicine composition is capsules, tablets, granules, powder, oral liquid or pills, and in order to realize the above formulation, pharmaceutically acceptable auxiliary materials are added when the formulation is prepared, such as: fillers, disintegrants, lubricants, suspending agents, binders, sweeteners, flavoring agents, preservatives, bases, and the like. The filler comprises: starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose, etc.; the disintegrating agent comprises: starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, crospolyvinylpyrrolidone, low-substituted hydroxypropylcellulose, croscarmellose sodium, etc.; the lubricant comprises: magnesium stearate, sodium lauryl sulfate, talc, silica, and the like; the suspending agent comprises: polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methylcellulose, and the like; the adhesive comprises starch slurry, polyvinylpyrrolidone, hydroxypropyl methylcellulose, etc.; the sweetener comprises: saccharin sodium, aspartame, sucrose, sodium cyclamate, glycyrrhetinic acid, and the like; the flavoring agent comprises: sweeteners and various essences; the preservative comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its salts, benzalkonium bromide, chloroacetidine acetate, eucalyptus oil, etc.; the matrix comprises: PEG6000, PEG4000, insect wax, etc. In order to realize the traditional Chinese medicine pharmacy, other pharmaceutically acceptable auxiliary materials (auxiliary materials recorded in each dosage form in the 12 th month and 1 st edition of Shanghai science Press 1997) are required to be added when preparing the dosage forms.
To clarify the activity of the Chinese medicinal composition of the present invention for treating non-infectious urethral syndrome, the following experiments were conducted with the medicament prepared according to the method of example 1 (hereinafter referred to as the present invention medicament) to confirm the clinical effects of the pharmaceutical composition for treating non-infectious urethral syndrome, demonstrating its new use in the pharmaceutical field.
Clinical data
1.1 general data: 78 patients were collected as noninfectious urethral syndrome collected in 2009 and 2012 in the Ridge Hospital in Hebei. In all cases, the symptoms of frequent micturition and dysuria last for more than 1 year, the clinical manifestations are prominent in frequent micturition, the average micturition time per hour is 2-3 times per hour, and the urine volume per time is small, and more obvious mental factors exist. The patients were randomly divided into 39 experimental groups and 39 control groups, and the two groups of patients were compared (P > 0.05) in terms of age, sex, disease course, disease distribution and complications without significant difference and were comparable.
1.2 case inclusion criteria were: (1) frequent urination and uncomfortable urination; (2) the count of the middle section urine bacteria culture is negative for 3 times; (3) clinically there is no evidence of urinary tract infection by other microorganisms, and urine is normal.
1.3 case exclusion criteria: eliminating gynecological examination abnormality; the abnormal position of the urethra is eliminated, the meatus caruncle of the urethra is found, and the obvious lesion in the bladder is found by the urethral examination and the cystoscopy; eliminating urinary tract tubercle bacillus, anaerobe and fungus infection; for patients with history of unclean sexual intercourse, urinary tract chlamydia and gonococcal infection are excluded.
Method of treatment
The control group is administered with diazepam 2.5 mg and oryzanol 20mg, and the test group is administered with the inventive medicine 2-4 capsules 3 times daily. The treatment course is 4 weeks, and the medicine is continuously applied for 2 treatment courses.
Observation of therapeutic effects
3.1 Observation indexes: tests of the disease are negative, and the results are difficult to compare before and after the test, so the symptom relief degree of the frequent micturition before and after treatment and the like is adopted as the curative effect evaluation index.
3.2 curative effect standard: and (3) healing: the frequent micturition is completely relieved, the times of micturition and the urine volume per time are recovered to be normal, the urgency of urination and the pain of urination disappear; improvement: the frequent micturition is improved, the times of micturition are reduced by more than 50 percent compared with those before treatment, the urine volume is obviously increased each time, and the urgent micturition and the pain of urination disappear; and (4) invalidation: the frequent micturition is not improved, but is accompanied by urgent micturition and odynuria.
3.3 statistical method all data are processed by statistical software SPSS 11.5; the metering data adopts t inspection; technical data adoption of x2Checking; for parameters
And (4) showing.
Results
4.1; the results of the comparison of the curative effect are shown in the table 1:
TABLE 1 comparison of the two therapeutic effects
Note: comparison of P <0.05 with control group
4.2 comparing the clinical symptoms and the disappearance rate of the physical signs, the control group and the test group have urgent micturition, painful urination and frequent micturition in all cases, wherein the control group has 28 lumbago symptoms and 30 hypodynamia symptoms, the test group has 25 lumbago symptoms and 33 hypodynamia symptoms, and the test results are shown in the table 2:
TABLE 2 comparison of clinical symptom and disappearance rate of physical signs
Note: comparison of P <0.05 with control group
4.3 summary: the experimental results show that the medicament for treating non-infectious urethral syndrome can cure 25 cases, improve 13 cases and have 1 case of no effect, the total effective rate reaches 97.4%, and the significant difference P is less than 0.05 compared with a control group; on the aspect of clinical symptoms and sign changes, the medicine has significant differences after treatment compared with a control group, wherein the significant differences have significant differences on the disappearance rates of the signs of treating urgent micturition, frequent micturition and lumbago compared with the control group, P is less than 0.05, and the significant differences have significant differences on the disappearance rates of the signs of dysuria and hypodynamia, and P is less than 0.05. Clinical tests prove that the medicament can obviously improve the treatment effect of patients with non-infectious urethral syndrome and improve the urination state, has better curative effect than the conventional treatment of pure western medicines, is a pure Chinese medicinal preparation, has no obvious toxic or side effect, and has wide application prospect.
Detailed Description
Example 1: preparation of the inventive pharmaceutical capsules
Prescription:
astragalus root 70 g talcum 14 g selfheal 21 g ligustrum japonicum 14 g
Litchi seed 21 g amber 2.1 g cinnamon 2.8 g phellodendron bark 7 g
The preparation method comprises the following steps:
(1) weighing the traditional Chinese medicinal materials according to the prescription amount, respectively cleaning and crushing;
(2) extracting radix astragali and cortex Phellodendri with 60% ethanol under reflux for 2 times, 10 times for the first time and 2 hours and 8 times for the second time for 1 hour, filtering the extractive solutions, mixing, recovering ethanol under reduced pressure, concentrating to obtain fluid extract with relative density of 1.20, and vacuum drying to obtain dry extract;
(3) extracting fructus Ligustri Lucidi with 8 times of 80% ethanol under reflux for 2 times (2 hr each time), filtering the extractive solutions, mixing, recovering ethanol under reduced pressure, concentrating to obtain fluid extract with relative density of 1.20, and vacuum drying to obtain dry extract;
(4) soaking the cinnamon in 6 times of water for 1 hour, extracting volatile oil for 4 hours, collecting the volatile oil in another container, filtering and collecting a water extracting solution, and reserving residues for later use;
(5) taking selfheal, lychee seeds and the residue obtained in the step (4), adding 9 times of water, decocting twice, decocting for 2 hours for the first time and 1.5 hours for the second time, filtering the extracting solution, combining, adding the aqueous solution obtained in the step (4), concentrating into clear paste with the relative density of 1.20, drying in vacuum, mixing the obtained dry paste with the dry paste obtained in the step (2) and the dry paste obtained in the step (3), and crushing into 100-mesh powder for later use;
(6) pulverizing pulvis Talci and Succinum into 100 mesh powder;
(7) uniformly mixing the dry paste powder obtained in the step (5), the fine powder obtained in the step (6) and a proper amount of auxiliary materials, using 80% ethanol as a binding agent, stirring at a high speed for granulation, granulating at 60 ℃, drying and finishing;
(8) and (4) screening out fine powder, spraying the volatile oil obtained in the step (4), uniformly mixing with the granules, sealing, and encapsulating to obtain the capsule.
Example 2: preparation of the pharmaceutical tablet of the invention
Prescription:
astragalus root 30 g talcum 7 g selfheal 10 g ligustrum japonicum 7 g
Litchi seed 10 g amber 1 g cinnamon 1.5 g phellodendron bark 3 g
The preparation method comprises the following steps:
(1) weighing the traditional Chinese medicinal materials according to the prescription amount, respectively cleaning and crushing;
(2) extracting radix astragali and cortex Phellodendri with 50% ethanol under reflux for 2 times, 9 times for the first time and 3 hr for the second time and 8 times for 1.5 hr, filtering the extractive solutions, mixing, recovering ethanol under reduced pressure, and concentrating to obtain fluid extract with relative density of 1.25;
(3) extracting fructus Ligustri Lucidi with 6 times of 70% ethanol under reflux for 1 hr for 1 time, filtering the extractive solutions, mixing, recovering ethanol under reduced pressure, and concentrating to obtain fluid extract with relative density of 1.25;
(4) soaking the cinnamon in 4 times of water for 1 hour, extracting volatile oil for 2 hours, collecting the volatile oil in another container, filtering and collecting a water extracting solution, and reserving residues for later use;
(5) taking selfheal, lychee seeds and the residues obtained in the step (4), adding 8 times of water, decocting twice, decocting for 1 hour for the first time and 2 hours for the second time, filtering the extracting solution, mixing, adding the aqueous solution obtained in the step (4), and concentrating into clear paste with the relative density of 1.20 for later use;
(6) pulverizing pulvis Talci and Succinum into 100 mesh fine powder;
(7) and making into tablet by conventional method.
Example 3: preparation of the inventive pharmaceutical capsules
Prescription:
astragalus root 150 parts talc 28 parts prunella spike 40 parts ligustrum japonicum 28 parts
40 parts of lychee seeds, 4 parts of amber, 6 parts of cinnamon and 15 parts of golden cypress.
(1) Weighing the traditional Chinese medicinal materials according to the prescription amount, respectively cleaning and crushing;
(2) extracting radix astragali and cortex Phellodendri with 70% ethanol under reflux for 2 times, the first time with 10 times of ethanol for 0.5 hr and the second time with 8 times of ethanol for 2 hr, filtering the extractive solutions, mixing, recovering ethanol under reduced pressure, concentrating to obtain fluid extract with relative density of 1.20, and vacuum drying to obtain dry extract;
(3) extracting fructus Ligustri Lucidi with 10 times of 90% ethanol under reflux for 3 times (3 hr each time), filtering the extractive solutions, mixing, recovering ethanol under reduced pressure, concentrating to obtain fluid extract with relative density of 1.20, and vacuum drying to obtain dry extract;
(4) soaking the cinnamon in 8 times of water for 2 hours, extracting volatile oil for 6 hours, collecting the volatile oil in another container, filtering and collecting a water extracting solution, and reserving residues for later use;
(5) taking selfheal, lychee seeds and the residue obtained in the step (4), adding 10 times of water, decocting twice, decocting for 3 hours for the first time and 1 hour for the second time, filtering the extracting solution, combining, adding the aqueous solution obtained in the step (4), concentrating into clear paste with the relative density of 1.25, drying in vacuum, mixing the obtained dry paste with the dry paste obtained in the step (2) and the dry paste obtained in the step (3), and crushing into 100-mesh powder for later use;
(6) pulverizing pulvis Talci and Succinum into 100 mesh powder;
(7) uniformly mixing the dry paste powder obtained in the step (5), the fine powder obtained in the step (6) and a proper amount of auxiliary materials, using 80% ethanol as a binding agent, stirring at a high speed for granulation, granulating at 70 ℃, drying and finishing;
(8) and (4) screening out fine powder, spraying the volatile oil obtained in the step (4), uniformly mixing with the granules, sealing, and encapsulating to obtain the capsule.
Example 4: preparation of the inventive medicinal pill
Prescription:
astragalus root 30 g talcum 28 g selfheal 10 g ligustrum japonicum 28 g
Litchi seed 10 g amber 4 g cinnamon 1.5 g phellodendron bark 15 g
The preparation method comprises the following steps: making into pill by conventional method.
Example 5: preparation of the medicinal oral liquid
Prescription: astragalus root 34 g talcum 12 g selfheal 19 g ligustrum japonicum 18 g
Litchi seed 25 g amber 2.5 g cinnamon 4.5 g phellodendron bark 13 g
The preparation method comprises the following steps: making into oral liquid by conventional method.
Claims (9)
1. The application of the composition in preparing the medicine for treating non-infectious urethral syndrome is characterized in that the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight:
30-150 parts of astragalus mongholicus, 7-28 parts of talcum, 10-40 parts of selfheal, 7-28 parts of glossy privet fruit
10-40 parts of lychee seed, 1-4 parts of amber, 1.5-6 parts of cinnamon, and 3-15 parts of phellodendron bark.
2. The application of claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight:
70 parts of astragalus mongholicus, 14 parts of talcum, 21 parts of selfheal and 14 parts of glossy privet fruit
Litchi seeds 21 parts, amber 2.1 parts, cinnamon 2.8 parts, phellodendron bark 7 parts.
3. The application of claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight:
30 parts of astragalus mongholicus, 7 parts of talcum, 10 parts of selfheal and 7 parts of glossy privet fruit
Litchi seeds 10 parts of amber 1 part of cinnamon 1.5 parts of phellodendron bark 3 parts.
4. The application of claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight:
astragalus root 150 parts talc 28 parts prunella spike 40 parts ligustrum japonicum 28 parts
40 parts of lychee seeds, 4 parts of amber, 6 parts of cinnamon and 15 parts of golden cypress.
5. The application of claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight:
30 parts of astragalus mongholicus, 28 parts of talc, 10 parts of selfheal and 28 parts of glossy privet fruit
Litchi seeds 10 parts, amber 4 parts, cinnamon 1.5 parts, phellodendron bark 15 parts.
6. The use according to any one of claims 1 to 5, characterized in that the active ingredients of the Chinese medicinal composition are prepared by the following steps:
(1) weighing the traditional Chinese medicinal materials according to the weight proportion of the raw materials, respectively cleaning and crushing;
(2) extracting radix astragali and cortex Phellodendri with 50-70% ethanol under reflux for 1-3 times (0.5-3 hr each time), filtering the extractive solutions, mixing, recovering ethanol under reduced pressure, and concentrating to obtain fluid extract with relative density of 1.20-1.25;
(3) extracting fructus Ligustri Lucidi with 6-10 times of 70-90% ethanol under reflux for 1-3 times (1-3 hr each time), filtering the extractive solutions, mixing, recovering ethanol under reduced pressure, and concentrating to obtain fluid extract with relative density of 1.20-1.25;
(4) soaking cortex Cinnamomi in 4-8 times of water for 1-2 hr, extracting volatile oil for 2-6 hr,
collecting volatile oil in another container, filtering water extractive solution, and collecting residue;
(5) taking selfheal, lychee seeds and the residues obtained in the step (4), adding 8-10 times of water, decocting twice, wherein the first time is 1-3 hours, the second time is 1-2 hours, filtering the extracting solution, combining, adding the aqueous solution obtained in the step (4), and concentrating into clear paste with the relative density of 1.20-1.25 for later use;
(6) pulverizing pulvis Talci and Succinum into 100 mesh fine powder;
the clear paste obtained in the step (2), the clear paste obtained in the step (3), the volatile oil obtained in the step (4), the clear paste obtained in the step (5) and the fine powder obtained in the step (6) jointly form the active ingredients of the traditional Chinese medicine composition.
7. The use of any one of claims 1-5, wherein the formulation of the Chinese medicinal composition is in the form of a capsule, tablet, oral liquid or pill.
8. Use according to claim 7, characterized in that the capsules are made by the following steps:
(1) respectively cleaning and selecting the traditional Chinese medicinal materials, crushing, and weighing according to a proportion;
(2) extracting radix astragali and cortex Phellodendri with 50-70% ethanol under reflux for 0.5-3 hr for 1-3 times, filtering the extractive solutions, mixing, recovering ethanol under reduced pressure, concentrating to obtain fluid extract with relative density of 1.20-1.25, and vacuum drying to obtain dry extract;
(3) extracting fructus Ligustri Lucidi with 6-10 times of 70-90% ethanol under reflux for 1-3 times (1-3 hr for each time), filtering the extractive solutions, mixing, recovering ethanol under reduced pressure, concentrating to obtain fluid extract with relative density of 1.20-1.25, and vacuum drying to obtain dry extract;
(4) soaking cortex Cinnamomi in 4-8 times of water for 1-2 hr, extracting volatile oil for 2-6 hr,
collecting volatile oil with other container, wherein the oil yield is not less than l.0%, filtering the water extractive solution, and collecting the residue;
(5) taking selfheal, lychee seeds and the residue obtained in the step (4), adding 8-10 times of water, decocting twice, wherein the first time is 1-3 hours, the second time is 1-2 hours, filtering the extracting solution, combining, adding the aqueous solution obtained in the step (4), concentrating into clear paste with the relative density of 1.20-1.25, drying in vacuum, mixing the obtained dry paste with the dry paste obtained in the step (2), and crushing into 100-mesh powder for later use;
(6) pulverizing pulvis Talci and Succinum into 100 mesh powder;
(7) uniformly mixing the dry paste powder obtained in the step (5), the fine powder obtained in the step (6) and a proper amount of auxiliary materials, using 80% ethanol as a binding agent, stirring at a high speed for granulation, drying at 60-70 ℃, and finishing granules;
(8) and (4) screening out fine powder, spraying the volatile oil obtained in the step (4), uniformly mixing with the granules, sealing, and encapsulating to obtain the capsule.
9. Use according to claim 7, characterized in that the capsules are made by the following steps:
(1) weighing the traditional Chinese medicinal materials according to the prescription amount, respectively cleaning and crushing;
(2) extracting radix astragali and cortex Phellodendri with 60% ethanol under reflux for 2 times, 10 times for the first time and 2 hours and 8 times for the second time for 1 hour, filtering the extractive solutions, mixing, recovering ethanol under reduced pressure, concentrating to obtain fluid extract with relative density of 1.20-1.25, and vacuum drying to obtain dry extract;
(3) extracting fructus Ligustri Lucidi with 8 times of 80% ethanol under reflux for 2 times (2 hr each time), filtering the extractive solutions, mixing, recovering ethanol under reduced pressure, concentrating to obtain fluid extract with relative density of 1.20-1.25, and vacuum drying to obtain dry extract;
(4) soaking Cinnamomum cassia in 6 times of water for 1 hr, extracting volatile oil for 4 hr, collecting volatile oil with another container until the oil yield is not less than l.0%, filtering the water extractive solution, and collecting the residue;
(5) taking selfheal, lychee seeds and the residue obtained in the step (4), adding 9 times of water, decocting twice, decocting for 2 hours for the first time and 1.5 hours for the second time, filtering the extracting solution, combining, adding the aqueous solution obtained in the step (4), concentrating into clear paste with the relative density of 1.20-1.25, drying in vacuum, mixing the obtained dry paste with the dry paste obtained in the step (2) and the dry paste obtained in the step (3), and crushing into 100-mesh powder for later use;
(6) pulverizing pulvis Talci and Succinum into 100 mesh powder;
(7) uniformly mixing the dry paste powder obtained in the step (5), the fine powder obtained in the step (6) and a proper amount of auxiliary materials, using 80% ethanol as a binding agent, stirring at a high speed for granulation, drying at 60-70 ℃, and finishing granules;
(8) and (4) screening out fine powder, spraying the volatile oil obtained in the step (4), uniformly mixing with the granules, sealing, and encapsulating to obtain the capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310243458.5A CN104225034B (en) | 2013-06-19 | 2013-06-19 | Application of composition in preparing medicine for treating non-infectious urethral syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310243458.5A CN104225034B (en) | 2013-06-19 | 2013-06-19 | Application of composition in preparing medicine for treating non-infectious urethral syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104225034A CN104225034A (en) | 2014-12-24 |
| CN104225034B true CN104225034B (en) | 2020-01-21 |
Family
ID=52214510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310243458.5A Active CN104225034B (en) | 2013-06-19 | 2013-06-19 | Application of composition in preparing medicine for treating non-infectious urethral syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104225034B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111840401B (en) * | 2019-04-22 | 2023-05-09 | 石家庄以岭药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating gastrointestinal hemorrhage |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1778358A (en) * | 2004-11-24 | 2006-05-31 | 河北以岭医药研究院有限公司 | Medicine for treating prostatic accrementition and its preparation |
| CN101618110A (en) * | 2008-07-03 | 2010-01-06 | 北京以岭药业有限公司 | Application of Chinese medicinal composition in preparing medicament for treating urinary calculi |
| CN101618103A (en) * | 2008-07-03 | 2010-01-06 | 北京以岭药业有限公司 | Application of Chinese medicinal composition in preparing medicament for treating chronic glomerulonephritis |
-
2013
- 2013-06-19 CN CN201310243458.5A patent/CN104225034B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1778358A (en) * | 2004-11-24 | 2006-05-31 | 河北以岭医药研究院有限公司 | Medicine for treating prostatic accrementition and its preparation |
| CN101618110A (en) * | 2008-07-03 | 2010-01-06 | 北京以岭药业有限公司 | Application of Chinese medicinal composition in preparing medicament for treating urinary calculi |
| CN101618103A (en) * | 2008-07-03 | 2010-01-06 | 北京以岭药业有限公司 | Application of Chinese medicinal composition in preparing medicament for treating chronic glomerulonephritis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104225034A (en) | 2014-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103463539A (en) | Drug for treating eczema, and preparation method and use thereof | |
| CN102284049A (en) | Traditional Chinese medicine compound preparation for resisting ulcer and relieving chemoradiotherapeutic toxic and side effects, and preparation method and application thereof | |
| CN106334060B (en) | Pharmaceutical composition for treating obesity type polycystic ovarian syndrome | |
| CN101564458A (en) | Application of Chinese medicinal composition in preparing medicament for treating bronchitis | |
| WO2022160520A1 (en) | Pharmaceutical composition for treating cervical disc herniation, and preparation method therefor and application thereof | |
| CN105381132A (en) | Drug for treating thyroid nodule | |
| CN107468768B (en) | Qiang medicine composition and application thereof | |
| CN104225034B (en) | Application of composition in preparing medicine for treating non-infectious urethral syndrome | |
| CN1895433A (en) | Chinese-medicinal composition for treating acne, its preparation and use | |
| CN101693084B (en) | Medical composition for treating epigastric pain yin deficiency syndrome and preparation method thereof | |
| CN104491459A (en) | Traditional Chinese medicine composition for treating tumors | |
| CN103157048B (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammation and preparation method thereof | |
| CN101732469B (en) | Application of Chinese medicinal composition in preparation of medicament for treating aphonia | |
| CN104622995A (en) | Pharmaceutical composition for treating chronic superficial gastritis and preparation method of pharmaceutical composition | |
| CN105194355A (en) | Traditional Chinese medicine preparation for treating primary hypertension | |
| CN104225035B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating male infertility | |
| CN103800736A (en) | Pharmaceutical composition for treating hypertensive nephrosclerosis and application of pharmaceutical composition | |
| CN102727766A (en) | Traditional Chinese medicinal preparation for treating comprehensive hemorrhoids, and preparation method thereof | |
| CN102225154B (en) | Medicament composition for treating pulmonary fibrosis | |
| CN101879227B (en) | Chinese medicinal composition for treating protrusion of lumbar intervertebral disci and preparation method thereof | |
| CN113876889B (en) | Traditional Chinese medicine composition for treating premature ejaculation | |
| CN102406790A (en) | Traditional Chinese medicine capsule for treating hyperplasia of mammary glands and preparation method thereof | |
| CN102600436A (en) | Traditional Chinese medicine compound preparation for treating gastric cancer and preparation method thereof | |
| CN109793846B (en) | A Chinese medicinal composition | |
| CN101618118B (en) | Application of Chinese medicinal composition in preparing medicament for treating cystitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |